

**REMOVAL, PRE-CONCENTRATION AND
DETERMINATION OF SELECTED
PHARMACEUTICALS FROM ENVIRONMENTAL
WATER SAMPLES**

RANIA EDREES ADAM MOHAMMAD

UNIVERSITI SAINS MALAYSIA

2022

**REMOVAL, PRE-CONCENTRATION AND
DETERMINATION OF SELECTED
PHARMACEUTICALS FROM ENVIRONMENTAL
WATER SAMPLES**

by

RANIA EDREES ADAM MOHAMMAD

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

June 2022

DECLARATION

I declare that the content which is presented in this thesis is my work which was done at Universiti Sains Malaysia unless informed otherwise. The thesis has not been previously submitted for any other degree.

Name of Student:
Rania Edrees Adam Mohammad
Matric number: P-KD0005/18(R)
Passport number: P08674329

Name of Supervisor:
Dr Mazidatulakmam Miskam

ACKNOWLEDGEMENT

First and foremost, I would like to thank Almighty Allah for giving me the strength, knowledge, ability and opportunity to undertake this program. Without His blessings, this achievement would not have been possible.

I would like to sincerely thank my main supervisor, Dr. Mazidatulakmam Miskam for her guidance, understanding, patience and most importantly, she has provided positive encouragement and a warm spirit, enabling me to complete this research. It has been a great pleasure and honour to have her as my supervisor. I also owe many thanks to my co-supervisors Prof. Abdalla Ahmed Elbashir, Prof. Bahruddin Saad, Dr. Noorfatimah Yahaya and Dr. Jamilah Binti Karim for their guidance, kindness and advice throughout my project. I would also like to express my greatest gratitude to the Ministry of Higher Education, Malaysia for financial assistance through Fundamental Research Grant Scheme (FRGS/1/2020/STG04/USM/02/5).

My appreciation goes to Universiti Sains Malaysia for providing me an enabling environment to conduct my research. I also want to extend my earnest appreciation to Assoc. Prof. Dr. Melati Khairudean and Prof. Dr. Rohana Adnan for their kind support and guidance and endowment me the honour to join School of Chemical Science as graduate assistance. My thanks also to Open University of Sudan for their support. I thank you wholeheartedly.

I am also grateful and highly indebted to my dear friend Sara Abdelrahman Abuelmaali, for her moral support and all her uncountable contributions. May Allah reward her abundantly. I also-wish to express my profound appreciation to my caring kind aunt Dr. Fatima Ismail Adam for her support and courage. My deepest gratitude

also goes to all my extended family members, more so I would like to thank my dearest father, Edrees Adam and my mother Badria Mohamad Bahredin for their love, support and earnest prayers. Finally, I would like to extend my appreciation and acknowledge the efforts of all my lab mates, colleagues and friends too numerous to mention. May Allah shower His blessings on you all for contributing to the actualization of this study.

TABLE OF CONTENTS

| | |
|---|---------------|
| DECLARATION..... | ii |
| ACKNOWLEDGEMENT..... | iii |
| TABLE OF CONTENTS..... | v |
| LIST OF TABLES | xi |
| LIST OF FIGURES | xiii |
| LIST OF ABBREVIATIONS | xx |
| LIST OF SYMBOLS | xxiii |
| LIST OF APPENDICES | xxv |
| ABSTRAK | xxvi |
| ABSTRACT | xxviii |
| CHAPTER 1 INTRODUCTION..... | 1 |
| 1.1 Background of the study | 1 |
| 1.2 Problem statement..... | 5 |
| 1.3 Objectives..... | 7 |
| 1.4 Outline of the thesis..... | 7 |
| CHAPTER 2 LITERATURE REVIEW..... | 9 |
| 2.1 Pharmaceuticals..... | 9 |
| 2.1.1 Nonsteroidal anti-inflammatory drugs | 10 |
| 2.1.2 Antibiotics | 14 |
| 2.2 Sample preparation..... | 17 |
| 2.2.1 Solvent-based microextraction..... | 21 |
| 2.2.2 Sorbent-based microextraction..... | 28 |
| 2.3 Adsorbents..... | 33 |
| 2.3.1 Graphene oxide based adsorbents | 33 |
| 2.3.2 Magnetic graphene oxide based adsorbents..... | 36 |

| | | |
|-----------------------------------|---|-----------|
| 2.3.3 | Deep eutectic solvent based ferrofluid..... | 40 |
| CHAPTER 3 METHODOLOGY..... | | 46 |
| 3.1 | Chemicals and reagents..... | 46 |
| 3.2 | Preparation of standards and sample solutions | 47 |
| 3.3 | Real samples collection..... | 48 |
| 3.4 | Part I: Vortex-assisted liquid-liquid microextraction with back extraction coupled with high-performance liquid chromatography for the determination of nonsteroidal anti-inflammatory drugs in environmental water samples.... | 50 |
| 3.4.1 | HPLC analysis..... | 50 |
| 3.4.2 | VALLME-BE procedure..... | 50 |
| 3.4.3 | Method validation | 52 |
| 3.4.3(a) | Linearity..... | 52 |
| 3.4.3(b) | Limit of detection and limit of quantification..... | 53 |
| 3.4.3(c) | Precision | 53 |
| 3.4.3(d) | Recovery..... | 54 |
| 3.4.3(e) | Enrichment Factor | 54 |
| 3.5 | Part II: Synthesis, characterization, and adsorption performances of graphene oxide magnetite adsorbents and graphene oxide magnetite-deep eutectic solvent ferrofluid for the removal of fluoroquinolones..... | 54 |
| 3.5.1 | Synthesis of graphene oxide..... | 55 |
| 3.5.2 | Synthesis of graphene oxide magnetite..... | 55 |
| 3.5.3 | Synthesis of DESs | 56 |
| 3.5.4 | Synthesis of graphene oxide magnetite functionalized with DES ferrofluid..... | 58 |
| 3.5.5 | Characterizations of the synthesized adsorbents..... | 58 |
| 3.5.6 | Instrumentations | 60 |
| 3.5.7 | Batch adsorption method..... | 60 |
| 3.5.8 | Optimization parameter of batch adsorption method..... | 61 |
| 3.5.8(a) | Effect of solution pH | 62 |

| | | | |
|-------|----------|---|----|
| | 3.5.8(b) | Effect of contact time..... | 62 |
| | 3.5.8(c) | Effect of adsorbent dosage..... | 62 |
| | 3.5.8(d) | Effect of initial concentration and temperature | 62 |
| 3.5.9 | | Adsorption performances | 62 |
| | 3.5.9(a) | Adsorption kinetic | 63 |
| | 3.5.9(b) | Adsorption isotherm | 66 |
| | 3.5.9(c) | Thermodynamic | 70 |
| | 3.5.9(d) | Validation of kinetic models..... | 71 |
| 3.6 | | Part III: Graphene oxide magnetite functionalized deep eutectic solvent ferrofluid based liquid phase microextraction for the determination of fluoroquinolones in Langat River Basin, Selangor, Malaysia. | 72 |
| | 3.6.1 | Chromatographic conditions | 72 |
| | 3.6.2 | GO@Fe ₃ O ₄ -DES FF-LPME procedure..... | 73 |
| | 3.6.3 | Optimization of ferrofluid based liquid phase microextraction | 75 |
| | | 3.6.3(a) Type of DES | 75 |
| | | 3.6.3(b) DES ratio | 75 |
| | | 3.6.3(c) Solution pH..... | 75 |
| | | 3.6.3(d) Volume of GO@Fe ₃ O ₄ -DES FF | 75 |
| | | 3.6.3(e) Effect of extraction time | 75 |
| | | 3.6.3(f) Type of desorption solvent | 76 |
| | | 3.6.3(g) Desorption time | 76 |
| | | 3.6.3(h) Desorption solvent volume | 76 |
| | | 3.6.3(i) Effect of sample volume | 76 |
| | 3.6.4 | Method validation | 76 |
| | | 3.6.4(a) Linearity..... | 76 |
| | | 3.6.4(b) Limit of detection and limit of quantification..... | 77 |
| | | 3.6.4(c) Precision | 77 |
| | | 3.6.4(d) Recovery | 77 |

| | | |
|------------------|---|-----------|
| CHAPTER 4 | RESULT AND DISCUSSION..... | 78 |
| 4.1 | Part I: Vortex-assisted liquid-liquid microextraction with back extraction (VALLME-BE) coupled with high performance liquid chromatography for the determination of nonsteroidal anti-inflammatory drugs in environmental water samples | 78 |
| 4.1.1 | Optimization of VALLME-BE method | 78 |
| 4.1.1(a) | Type of extraction solvent | 78 |
| 4.1.1(b) | Volume of extraction solvent..... | 80 |
| 4.1.1(c) | Sample pH | 81 |
| 4.1.1(d) | Vortexing speed and time in VALLME | 82 |
| 4.1.1(e) | NaOH concentration and volume | 84 |
| 4.1.1(f) | Vortexing speed and time in BE..... | 85 |
| 4.1.2 | Method validation | 87 |
| 4.1.3 | Analysis of real samples..... | 88 |
| 4.2 | Part II: Synthesis, characterization, and adsorption performances of graphene oxide magnetite adsorbents and graphene oxide magnetite-deep eutectic solvent ferrofluid for the removal of fluoroquinolones..... | 92 |
| 4.2.1 | Preliminary analysis | 93 |
| 4.2.1(a) | Selection of GO and Fe ₃ O ₄ compositions..... | 93 |
| 4.2.1(b) | Selection of type and compositions of DES | 95 |
| 4.2.2 | Characterization of the synthesized materials..... | 97 |
| 4.2.2(a) | Fourier Transform infrared spectroscopy | 97 |
| 4.2.2(b) | Scanning electron microscopy-energy dispersion X-ray analysis | 101 |
| 4.2.2(c) | Transmission electron microscopy analysis | 103 |
| 4.2.2(d) | Nitrogen adsorption analysis | 106 |
| 4.2.2(e) | Vibrating sample magnetometer..... | 107 |
| 4.2.2(f) | X- ray diffraction analysis | 109 |
| 4.2.2(g) | Thermogravimetric analysis | 110 |
| 4.2.3 | Optimization parameter of batch adsorption method..... | 112 |

| | | |
|---|---|------------|
| 4.2.3(a) | Effect of GO@Fe ₃ O ₄ and GO@Fe ₃ O ₄ -DES FF dosage | 112 |
| 4.2.3(b) | Effect of pH | 114 |
| 4.2.3(c) | Effect of contact time..... | 117 |
| 4.2.3(d) | Effect of initial concentration and temperature | 119 |
| 4.2.4 | Adsorption kinetic, isotherm, and thermodynamic studies | 122 |
| 4.2.4(a) | Adsorption kinetic model | 122 |
| 4.2.4(b) | Adsorption isotherm study..... | 126 |
| 4.2.4(c) | Thermodynamic study | 138 |
| 4.2.5 | Reusability of GO@Fe ₃ O ₄ for the removal of selected FQs..... | 140 |
| 4.3 | Part III: Graphene oxide magnetite functionalized deep eutectic solvent ferrofluid based liquid phase microextraction for the determination of fluoroquinolones in Langat River Basin, Selangor, Malaysia. | 142 |
| 4.3.1 | Exploration of potential extraction mechanism on GO@Fe ₃ O ₄ -DES FF | 142 |
| 4.3.2 | Optimization of ferrofluid based liquid phase microextraction ... | 145 |
| 4.3.2(a) | Type of DES | 145 |
| 4.3.2(b) | Type of desorption solvent | 146 |
| 4.3.2(c) | Ferrofluid composition | 147 |
| 4.3.2(d) | Volume of GO@Fe ₃ O ₄ -DES FF..... | 149 |
| 4.3.2(e) | Effect of sample pH..... | 151 |
| 4.3.2(f) | Effect of extraction time | 152 |
| 4.3.2(g) | Desorption time | 153 |
| 4.3.2(h) | Desorption solvent volume | 154 |
| 4.3.2(i) | Effect of sample volume..... | 155 |
| 4.3.3 | Method validations..... | 156 |
| 4.3.4 | Real samples analysis..... | 157 |
| CHAPTER 5 CONCLUSION AND RECOMMENDATIONS | | 164 |
| 5.1 | Conclusion..... | 164 |

| | | |
|-----|---|------------|
| 5.2 | Recommendations for future studies..... | 167 |
| | REFERENCES..... | 169 |
| | APPENDICES | |
| | LIST OF PUBLICATIONS AND CONFERENCES | |

LIST OF TABLES

| | Page |
|------------|--|
| Table 2.1 | Sample preparation techniques for NSAIDs analysis..... 12 |
| Table 2.2 | Removal of FQs using different adsorbents..... 16 |
| Table 2.3 | FQs sample preparation based on LPME..... 18 |
| Table 2.4 | Major modification on solvent microextraction techniques.....23 |
| Table 2.5 | FF-based LPME for different organic and inorganic chemicals.....27 |
| Table 2.6 | Sorbent based microextraction main techniques and their features. ...30 |
| Table 2.7 | The applications of GO for the removal of pharmaceuticals.36 |
| Table 2.8 | Principal preparation methods of iron oxide nanoparticles iron nanoparticle (Zhu et al., 2018).37 |
| Table 2.9 | Summary of application of graphene oxide magnetic nanoparticle for MSPE.....42 |
| Table 2.10 | The applications of FF based DES in LPME.....44 |
| Table 3.1 | Chemical structure, pK_a , and $\log P$ values for the selected NSAIDs and FQs47 |
| Table 4.1 | Method validation of the developed VALLME-BE method for ketoprofen, naproxen, diclofenac and ibuprofen.....89 |
| Table 4.2 | Recoveries obtained by spiking different matrices of environmental water samples with ketoprofen, naproxen, diclofenac, and ibuprofen.....92 |
| Table 4.3 | EDX analysis of GO, GO@Fe ₃ O ₄ , and GO@Fe ₃ O ₄ -DES FF..... 103 |
| Table 4.4 | BET analysis results of synthesized adsorbent materials..... 106 |
| Table 4.5 | Kinetic parameters for the adsorption of selected FQs compounds onto GO@Fe ₃ O ₄ 123 |

| | | |
|------------|--|-----|
| Table 4.6 | Kinetic parameters for the adsorption of selected FQs compounds onto GO@Fe ₃ O ₄ -DES FF. | 124 |
| Table 4.7 | Isotherm parameters for the removal of ofloxacin using GO@Fe ₃ O ₄ | 128 |
| Table 4.8 | Isotherm parameters for the removal of enrofloxacin using GO@Fe ₃ O ₄ | 129 |
| Table 4.9 | Isotherm parameters for the removal of gemifloxacin using GO@Fe ₃ O ₄ | 130 |
| Table 4.10 | Isotherm parameters for the removal of sparfloxacin using GO@Fe ₃ O ₄ | 131 |
| Table 4.11 | Isotherm parameters for the removal of ofloxacin using GO@Fe ₃ O ₄ -DES FF. | 132 |
| Table 4.12 | Isotherm parameters for the removal of enrofloxacin using GO@Fe ₃ O ₄ -DES FF. | 133 |
| Table 4.13 | Isotherm parameters for the removal of gemifloxacin using GO@Fe ₃ O ₄ -DES FF. | 134 |
| Table 4.14 | Isotherm parameters for the removal of sparfloxacin using GO@Fe ₃ O ₄ -DES FF. | 135 |
| Table 4.15 | The value of ΔH , ΔS and ΔG for the removal of OFL, SPR, GEM and ENR using GO@Fe ₃ O ₄ and GOFe ₃ O ₄ -DES FF..... | 139 |
| Table 4.16 | Analytical performances of GO@Fe ₃ O ₄ -DES FF-LPME method using GO@Fe ₃ O ₄ -DES FF..... | 158 |
| Table 4.17 | Description of site sampling points along Langat River Basin, Selangor. | 160 |
| Table 4.18 | Recoveries obtained by spiking of OFL, ENR, SPR, and GEM in water samples from Langat basin river Selangor, towards GO@Fe ₃ O ₄ -DES FF LPME. | 161 |

LIST OF FIGURES

| | Page |
|------------|--|
| Figure 2.1 | Major microextraction techniques.....20 |
| Figure 2.2 | Schematic diagram of MSPE (Wierucka & Biziuk, 2014)32 |
| Figure 2.3 | Schematic illustration of the structure of graphene, graphite powder, graphite oxide, and graphene oxide (Zhou et al., 2019).....35 |
| Figure 2.4 | Show type of graphene based magnetic nanoparticles (a) encapsulated (b) surface decorated (Boncel et al., 2012).39 |
| Figure 3.1 | Map for the sample collection along Langat River Basin, Selangor, Malaysia (Karim et al., 2018)49 |
| Figure 3.2 | Schematic diagram of the proposed VALLME-BE method51 |
| Figure 3.3 | Schematic of the synthesis of (a) GtO, (b) GO@Fe ₃ O ₄ , (c) choline chloride-ethylene glycol deep eutectic solvent (DES) and (d) GO@Fe ₃ O ₄ -DES FF.57 |
| Figure 3.4 | Batch adsorption method for the removal of OFL, ENR, GEM, and SPR.....61 |
| Figure 3.5 | Schematic diagram of the proposed GO@Fe ₃ O ₄ -DES FF-LPME method.....74 |
| Figure 4.1 | Effect of type of extraction solvent on peak areas of NSAIDs. (VALLME conditions: volume of sample, 10 mL; volume of extraction solvent, 250 μL; pH of the solution, not adjusted; vortex speed, 3000 rpm; vortex time, 60 s; back extraction conditions: NaOH volume, 20 μL; NaOH concentration, 0.05 M; vortex speed, 3000 rpm; extraction time, 60 s; solution pH, neutral)79 |
| Figure 4.2 | Effect of volume of extraction solvent on the peak areas of NSAIDs. (VALLME conditions: sample volume, 10 mL; type of extraction solvent, butyl acetate; 250 μL; solution pH, not adjusted; vortex speed, 3000 rpm; vortex time, 60 s; back |

| | | |
|------------|--|----|
| | extraction conditions: NaOH volume, 20 μ L; NaOH concentration, 0.05 M; vortex speed, 3000 rpm; vortex speed time, 60 s)..... | 80 |
| Figure 4.3 | Effect of pH on peak areas of NSAIDs. (VALLME conditions: sample volume, 10 mL; extraction solvent, butyl acetate; extraction solvent volume, 225 μ L; vortex speed, 3000 rpm; vortex time, 60 s; back extraction conditions: NaOH volume, 20 μ L, NaOH concentration, 0.05 M; vortex speed, 3000 rpm; extraction time, 60 s)..... | 81 |
| Figure 4.4 | Effect of (a) vortex speed and (b) vortex time on the peak areas of NSAIDs. (VALLME conditions: sample volume, 10 mL; extraction solvent, butyl acetate; extraction solvent volume, 225 μ L; solution pH, 3; back extraction conditions: NaOH volume, 20 μ L, NaOH concentration, 0.05 M; vortex speed, 3000 rpm; extraction time, 60 s)..... | 83 |
| Figure 4.5 | Effect of NaOH concentration on the peak areas of NSAIDs. (VALLME conditions: sample volume, 10 mL; extraction solvent, butyl acetate; extraction solvent volume 225 μ L, solution pH, 3; vortex speed, 2250 rpm; vortex time, 105s; back extraction conditions: NaOH volume, 20 μ L; vortex speed, 3000 rpm; vortex time, 60 s)..... | 84 |
| Figure 4.6 | Effect of NaOH volume on peak areas of NSAIDs. (VALLME conditions: sample volume, 10 mL; extraction solvent, butyl acetate; extraction solvent volume 225 μ L, solution pH, 3; vortex speed, 2250 rpm; vortex time, 105 s; back extraction conditions: NaOH concentration, 0.05 M; vortex speed, 3000 rpm; vortex time, 60 s)..... | 85 |
| Figure 4.7 | Effect of vortex speed in BE step on the peak area of NSAIDs. (VALLME conditions: sample volume, 10 mL; extraction solvent, butyl acetate; extraction solvent volume 225 μ L, solution pH, 3; vortex speed, 2250 rpm; vortex time, 105 s; back extraction conditions: NaOH concentration, 0.05 M; NaOH volume, 15 μ L; vortex time, 60 s)..... | 86 |

| | | |
|-------------|--|-----|
| Figure 4.8 | Effect of vortex time in BE step on peak areas of NSAIDs. (VALLME conditions: sample volume, 10 mL; extraction solvent, butyl acetate; extraction solvent volume 225 μ L, solution pH, 3; vortex speed, 2250 rpm; vortex time, 105 s; back extraction conditions: NaOH concentration, 0.05 M; NaOH volume, 15 μ L; vortex speed, 2250 rpm)..... | 87 |
| Figure 4.9 | HPLC-UV chromatograms corresponding to (a) 30 μ g L ⁻¹ spiked water sample, (b) 1000 μ g L ⁻¹ spiked seawater sample, and (c) blank seawater sample after undergoing VALLME-BE procedure. Column; C ₁₈ column Kintex (5 μ m \times 150 \times 4.6 mm), mobile phase; methanol and 30 mM formic acid (70:30, v/v), λ 220 nm, flow rate; 1 mL min ⁻¹ , KET (1), NAP (2), DIC (3), and IBU (4). | 90 |
| Figure 4.10 | HPLC-UV chromatograms corresponding to (a) 30 μ g L ⁻¹ spiked water sample, (b) 1000 μ g L ⁻¹ spiked river water sample, (c) blank river water sample after undergoing VALLME-BE procedure, Column; C ₁₈ column Kintex 5 μ size (150 \times 4.6 mm), 5 mm. mobile phase; methanol and 30 mM formic acid (70:30, v/v), λ 220 nm, flow rate; 1.00 mL min ⁻¹), KET (1), NAP (2), DIC (3), and IBU (4). | 91 |
| Figure 4.11 | Effect of (a) ratio of GO and Fe ₃ O ₄ nanoparticles (0.5: 50 (R1), 1: 50 (R2), 4: 50 (R3), 5: 50 (R4), and 6: 50 (R5)) and (b) type of adsorbent on the removal percentage of FQs..... | 94 |
| Figure 4.12 | Effect of (a) type of DES and (b) ratio of DES and Fe ₃ O ₄ on the removal percentage of FQs. | 96 |
| Figure 4.13 | FT-IR spectra of (a) graphite, (b) GtO, (c) Fe ₃ O ₄ and (d) GO@Fe ₃ O ₄ | 98 |
| Figure 4.14 | FT-IR spectra of (a) ChCl, (b) EG (c) ChCl:EG DES. | 99 |
| Figure 4.15 | FT-IR spectra of (a) ChCl:EG DES, (b) GO-Fe ₃ O ₄ (c) GO@Fe ₃ O ₄ -DES FF..... | 101 |
| Figure 4.16 | SEM micrographs of (a) GtO (b) Fe ₃ O ₄ (c) GO@Fe ₃ O ₄ and (d) (GO@Fe ₃ O ₄ -DES) FF (Magnification: 10 K and 12 K \times 10 μ m)... | 102 |

| | | |
|-------------|--|-----|
| Figure 4.17 | TEM micrographs of (a) GtO (b) Fe ₃ O ₄ (c) GO@Fe ₃ O ₄ and (d) GO@Fe ₃ O ₄ -DES FF (Magnification: 10K and 12K ×, 10μm). | 105 |
| Figure 4.18 | BET adsorption and desorption isotherms for (a) GtO, (b) Fe ₃ O ₄ , and (c) GO@Fe ₃ O ₄ | 107 |
| Figure 4.19 | VSM analysis of (a) Fe ₃ O ₄ (b) GO@Fe ₃ O ₄ (c) GO@Fe ₃ O ₄ -DES FF. | 108 |
| Figure 4.20 | XRD patterns of (a) GtO (b) Fe ₃ O ₄ (c) GO@Fe ₃ O ₄ , and (d) GO@Fe ₃ O ₄ -DES FF. | 110 |
| Figure 4.21 | TGA patterns of (a) GtO (b) Fe ₃ O ₄ (c) GO@Fe ₃ O ₄ , and (d) GO@Fe ₃ O ₄ -DES FF | 111 |
| Figure 4.22 | Effect of sorbent dosage of (a) GO@Fe ₃ O ₄ and (b) GO@Fe ₃ O ₄ -DES FF on the removal percentage of FQs. (Batch adsorption condition: Sample volume, 10 ml; pH, 7; contact time, 30 min; concentration 10 mg L ⁻¹)..... | 113 |
| Figure 4.23 | Effect of solution pH on the removal percentage of OFL, ENR, SPR, and GEM using (a) GO@Fe ₃ O ₄ and (b) GO@Fe ₃ O ₄ -DES FF. (Batch adsorption condition: Sample volume, 10 ml; contact time, 30 min; dosage, 20 mg and 200 μL for FF; concentration, 10 mg L ⁻¹)..... | 115 |
| Figure 4.24 | Effect of contact time on the removal percentage of OFL, ENR, SPR, and GEM using (a) GO@Fe ₃ O ₄ and (b) GO@Fe ₃ O ₄ -DES FF. (Batch adsorption condition: Sample volume, 10 ml; pH, 7; concentration 10 mg L ⁻¹ , dosage, 20 mg and 200 μL for FF) | 118 |
| Figure 4.25 | Effect of initial concentrations and temperatures on the removal percentage of (a) OFL, (b) ENR, (c) SPR and (d) GEM using GO@Fe ₃ O ₄ . (Batch adsorption condition: Sample volume, 10 ml; pH, 7; contact time, 30 min; dosage, 20 mg and 200 μL for FF)..... | 120 |
| Figure 4.26 | Effect of initial concentrations and temperatures on the removal percentage of (a) OFL, (b) ENR, (c) SPR and (d) GEM using GO@Fe ₃ O ₄ -DES FF. (Batch adsorption condition: Sample | |

| | | |
|-------------|--|-----|
| | volume, 10 ml; pH, 7; contact time, 30 min; concentration 10 mg L ⁻¹)..... | 121 |
| Figure 4.27 | Van't Hoff's plot for adsorption of OFL, ENR, GEM and SPR using (a) GO@Fe ₃ O ₄ and (b) GO@Fe ₃ O ₄ -DES FF..... | 140 |
| Figure 4.28 | Reusability of removal capacity on GO@Fe ₃ O ₄ towards OFL, ENR, GEM and SPR (batch adsorption conditions: sorbent dosage, 200 mg; initial concentration 10 mg L ⁻¹ ; adsorption time 60 min; pH 7 temperature 298 K; shaking speed; 250 rpm) | 141 |
| Figure 4.29 | Proposed mechanism of the interactions of OFL (model analyte) with GO@Fe ₃ O ₄ -DES FF. | 143 |
| Figure 4.30 | Effect of DES type on DES on the peak areas of OFL, ENR, GEM and SPR in GO@Fe ₃ O ₄ -DES FF LPME. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type: methanol (2 mL), FF composition: 28.5%, volume of FF: 300 μL, pH: neutral, extraction time: 30 mins, desorption time: 10 mins, the error bars indicate the standard deviations of three repeated determinations)..... | 146 |
| Figure 4.31 | Effect of types of desorption solvents on the peak areas of OFL, ENR, GEM and SPR in GO@Fe ₃ O ₄ -DES FF LPME. (Extraction conditions: volume of aqueous sample, 10 mL; DES type; DES (1), extraction solvent volume (2 mL), FF composition: 28.5%, volume of FF: 300 μL, pH: neutral, extraction time: 30 mins, desorption time: 10 mins, the error bars indicate the standard deviations of three repeated determinations). | 148 |
| Figure 4.32 | Effect of ferrofluid composition on the extraction of OFL, ENR, GEM, and SPR towards GO@Fe ₃ O ₄ -DES FF. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type and volume: (methanol: Ammonium 8:2 v/v) (2 mL), DES type; DES (1), the volume of FF: 300 μL, pH: neutral, extraction time: 30 mins, desorption time: 10 mins, the error bars indicate the standard deviations of three repeated determinations)..... | 149 |

| | | |
|-------------|---|-----|
| Figure 4.33 | Effect of volume of ferrofluid on extraction of OFL, ENR, GEM and SPR towards GO@Fe ₃ O ₄ -DES FF. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type and volume: (methanol: ammonium 8:2, v/v) (2 mL), DES type: DES (1), FF composition: 28.5%, pH: neutral, extraction time: 30 mins, desorption time: 10 mins. the error bars indicate the standard deviations of three repeated determinations). | 150 |
| Figure 4.34 | Effect of solution pH on extraction of OFL, ENR, GEM, and SPR towards GO@Fe ₃ O ₄ -DES FF. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type and volume: (methanol: Ammonium 8:2 v/v) (2 mL), DES type DES (1), FF composition: 28.5%, volume of FF: 200 μL, extraction time: 30 mins, desorption time: 10 mins, the error bars indicate the standard deviations of three repeated determinations). | 152 |
| Figure 4.35 | Effect of extraction time on the extraction of OFLO, ENR, GEM, and SPR towards GO@Fe ₃ O ₄ -DES FF. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type and volume: (methanol: Ammonium 8:2 v/v) (2 mL), DES type DES (1), FF composition: 28.5%, volume of FF: 200 μL, pH 6, desorption time: 10 mins, the error bars indicate the standard deviations of three repeated determinations). | 153 |
| Figure 4.36 | Effect of desorption time on the extraction of OFL, ENR, GEM, and SPR towards GO@Fe ₃ O ₄ -DES FF. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type and volume: (methanol: Ammonium 8:2 v/v) (2 mL), DES type DES (1), FF composition: 28.5%, volume of FF: 200 μL, pH 6, extraction time: 20 mins, the error bars indicate the standard deviations of three repeated determinations). | 154 |
| Figure 4.37 | Effect of volume of desorption solvent on the extraction of OFL, ENR, GEM, and SPR towards GO@Fe ₃ O ₄ -DES FF. (Extraction conditions: volume of aqueous sample, 10 mL; extraction solvent type: (methanol: Ammonium 8:2 v/v), DES type DES (1), FF | |

composition: 28.5%, volume of FF: 200 μL , pH 6, extraction time: 20 mins, desorption time: 3 mins, the error bars indicate the standard deviations of three repeated determinations)..... 155

Figure 4.38 Effect of sample volume on the extraction of OFL, ENR, GEM, and SPR towards GO@Fe₃O₄-DES FF. (Extraction conditions: extraction solvent type: (methanol: Ammonium 8:2 v/v) (500 μL), DES type DES (1), FF composition: 28.5%, volume of FF: 200 μL , pH 6, extraction time: 20 mins, desorption time: 3 mins, the error bars indicate the standard deviations of three repeated determinations)..... 156

Figure 4.39 HPLC-UV chromatograms corresponding to (a) blank river water sample (b) 5 $\mu\text{g L}^{-1}$ spiked river water sample, (c) 50 $\mu\text{g L}^{-1}$ spiked river water sample, (d) 500 $\mu\text{g L}^{-1}$ spiked river water sample after undergoing GO@Fe₃O₄-DES FF LPME procedure; column; C₁₈ column Kintex (5 $\mu\text{m} \times 150 \times 4.6$ mm), mobile phase; acetonitrile: 20 mM NaH₂PO₄ phosphate buffer (pH 3) (30:70, %v/v), λ 254 nm, flow rate; 0.8 mL min⁻¹). OFL (1), ENR (2), SPR (3), and GEM (4). 163

LIST OF ABBREVIATIONS

| | |
|--------------------------------|--|
| ACN | Acetonitrile |
| AC | Acceptor phase |
| ARGs | Antibiotic resistance genes |
| ARB | Antibiotic-resistant bacteria |
| BET | Brunauer-Emmett-Teller |
| BJH | Barrett-Joyner-Halenda |
| CE | Capillary electrophoresis |
| ChCl | Choline chloride |
| DES | Deep eutectic solvent |
| DLLME | Dispersive liquid-liquid microextraction |
| DIC | Diclofenac |
| DP | Donor phase |
| ENR | Enrofloxacin |
| EPA | Environmental Protection Agency |
| ECs | Emerging contaminants ECs |
| EU | European Union |
| EMA | European Medicines Agency |
| EF | Enrichment factor |
| EG | Ethylene glycol |
| Fe ₃ O ₄ | Magnetic nanoparticles |
| FTIR | Fourier Transform infrared spectroscopy |
| FF | Ferrofluid |
| FF-LPME | Ferrofluid liquid phase microextraction |

| | |
|---|---|
| FDA | Food and Drug Administration |
| FQs | Fluroquinolones |
| Fe ₃ O ₄ | Magnetic iron particles |
| GEM | Gemifloxacin |
| GO@Fe ₃ O ₄ | Graphene oxide magnetite |
| GO@Fe ₃ O ₄ -DES FF | Graphene oxide magnetite deep eutectic ferrofluid |
| GC | Gas chromatography |
| GLY | Glycerol |
| HPLC | High-Performance Liquid Chromatography |
| HBD | Hydrogen bond donors |
| HBA | Hydrogen bond acceptors |
| IBU | Ibuprofen |
| KET | Ketoprofen |
| LPME | Liquid phase microextraction |
| LOD | Limit of detection |
| LOQ | Limit of quantification |
| LLE | Liquid-liquid extraction |
| Ms | Magnetic saturation |
| MRL | Maximum residue limit |
| MeOH | Methanol |
| MSPE | Magnetic solid phase extraction |
| NSAIDs | Nonsteroid anti-inflammatory drugs |
| NAP | Naproxen |
| OFL | Ofloxacin |
| Ppm | Part per million |

| | |
|-----------|--|
| PzC | Point zero charge |
| RSD | Relative standard deviation |
| SD | Standard deviation |
| SPE | Solid Phase Extraction |
| SEM | Scanning electron microscopy |
| SPR | Sparfloxacin |
| TEM | Transmission electron microscopy |
| TGA | Thermogravimetric analysis |
| USEPA | US Environmental Protection Agency |
| VSM | Vibrating sample magnetometer |
| UV-Vis | Ultraviolet-visible |
| VALLME-BE | Vortex assist liquid liquid microextraction-back extraction |
| XRD | X-ray diffractometer |

LIST OF SYMBOLS

| | |
|------------------|---|
| pKa | Acid dissociation constant |
| q_e | Adsorption capacity (mg/g) |
| q_e cal | Calculated adsorption capacity (mg/g) |
| R^2 | Coefficient of determination |
| -COOH | Carboxyl group |
| cm | Centimeter |
| °C | Degree Celsius |
| Δ | Delta |
| R_L | Dimensional separation factor |
| Kd | Distribution coefficients |
| C_e | Equilibrium concentration of adsorbate (mg/L) |
| emu | Electromagnetic unit |
| ΔH° | Enthalpy |
| ΔS° | Entropy |
| q_e exp | Experimental adsorption capacity (mg/g) |
| g | Gram |
| Cf | Final concentration of adsorbate (mg/L) |
| KF | Freundlich constant |
| ΔG | Gibb's free energy |
| R | Gas constant (J/Kmol) |
| H ⁺ | Hydrogen ion |
| -OH | Hydroxyl group |
| 1/n | Heterogeneity Factor |

| | |
|------------------------|---|
| C_0 | Initial concentration of adsorbate (mg/L) |
| J | Joules |
| K | Kelvin |
| KJ | Kilojoules |
| L | Liter |
| μg | Microgram |
| mL | Mililiter |
| mm | Millimeter |
| mM | Millimolar |
| μL | Microliter |
| M | Molarity |
| q_m | Maximum adsorption capacity |
| mg | Milligram |
| N | Number of data points |
| nm | Nanometer |
| Δq (%) | Normalized standard deviation |
| Log P | Partition coefficient |
| π | Pi |
| θ | Theta |
| C | Thickness of boundary layer |
| V | Volume |
| λ_{max} | Wavelength of maximum absorbance |

LIST OF APPENDICES

- Appendix A Graphene oxide, PZC value, and BET
- Appendix B-1 Adsorption kinetic models plots of GO@Fe₃O₄
- Appendix B-2 Adsorption kinetic models plots of GO@Fe₃O₄-DES FF
- Appendix C-1 Adsorption Isotherm models plots for ofloxacin onto GO@Fe₃O₄
- Appendix C-2 Adsorption Isotherm models plots for enrofloxacin onto
GO@Fe₃O₄
- Appendix C-3 Adsorption Isotherm models plots for sparfloxacin onto
GO@Fe₃O₄
- Appendix C-4 Adsorption Isotherm models plots for gemifloxacin onto
GO@Fe₃O₄
- Appendix D-1 Adsorption Isotherm models plots for ofloxacin onto
GO@Fe₃O₄-DES FF
- Appendix D-2 Adsorption Isotherm models plots for enrofloxacin onto
GO@Fe₃O₄-DES FF
- Appendix D-3 Adsorption Isotherm models plots for sparfloxacin onto
GO@Fe₃O₄-DES FF
- Appendix D-4 Adsorption Isotherm models plots for gemifloxacin onto
GO@Fe₃O₄-DES FF

**PENYINGKIRAN, PRA-PEMEKATAN DAN PENENTUAN
FARMASEUTIKAL TERPILIH DARIPADA SAMPEL AIR
PERSEKITARAN**

ABSTRAK

Farmaseutikal merupakan pencemar memuncuk yang digunakan secara meluas dalam beberapa aplikasi termasuk ubatan manusia dan veterinar serta kegiatan pertanian. Analisis farmaseutikal bergantung pada pengkuatitan jitu farmaseutikal sasaran dari matriks kompleks, tetapi masih menjadi tugas yang sukar disebabkan oleh kepekatan yang rendah. Oleh itu, kajian ini memperlihatkan penggunaan kaedah penyediaan sampel yang berbeza untuk penentuan farmaseutikal terpilih di dalam sampel air. Teknik pengekstrakan mikro berdasarkan pengekstrakan mikro cecair-cecair berbantu vorteks dengan pengekstrakan belakang (VALLME-BE) telah dibangunkan untuk penentuan ubat anti-radang bukan steroid (NSAIDs) dinamakan, ketoprofen, naproxen, diclofenac dan ibuprofen. Prosedur ini dilakukan dengan menambahkan 225 μL butil asetat ke dalam 10 mL larutan piawai untuk prosedur VALLME, diikuti dengan pengekstrakan balik ke natrium hidroksida sebelum analisis kromatografi cecair berprestasi tinggi-UV-Vis (HPLC-UV-Vis). Di bawah keadaan optimum, kaedah yang dicadangkan memberikan kelinearan yang baik ($R^2 \geq 0.9809$), keboleholangan (%RSD; 3.4 – 16.1%) dan nilai had pengesanan (LOD) dan had kuantifikasi (LOQ) yang baik (ketoprofen (0.134 dan 0.407 $\mu\text{g L}^{-1}$), naproxen (0.015 dan 0.047 $\mu\text{g L}^{-1}$), diclofenac (0.03 dan 0.091 $\mu\text{g L}^{-1}$) and ibuprofen (0.05 dan 0.152 $\mu\text{g L}^{-1}$) telah diperolehi. Selain itu, penjerap grafena oksida (GO), grafena oksida bermagnet (GO@Fe₃O₄) dan grafena oksida bermagnet-larutan eutektik terdalam cecair ferro (GO@Fe₃O₄-DES FF) telah disintesis dan dicirikan. Peratusan

penyingkiran fluorokuinolon (ofloxacin, naproxen, gemifloxacin dan sparfloxacin) telah dioptimumkan berdasarkan kaedah penjerapan kelompok menggunakan penjerap yang telah disintesis. Di bawah keadaan optimum, prestasi penjerapan GO@Fe₃O₄ dan GO@Fe₃O₄-DES FF telah dikaji. Data eksperimen yang diperolehi menunjukkan semua analit sepadan dengan model kinetik tertib kedua pseudo dan model Freundlich. Kajian termodinamik menunjukkan yang proses penjerapan boleh terlaksana secara termodinamik, spontan dan eksotermik. Akhir sekali, kerana prestasi penjerapan GO@Fe₃O₄-DES FF adalah lebih baik berbanding GO@Fe₃O₄, ia telah dibangunkan lebih lanjut untuk diaplikasikan dalam GO@Fe₃O₄-DES FF- pengekstrakan mikro fasa cecair (LPME). Beberapa parameter termasuk jenis pelarut penyahjerap, isipadu cecair ferro, masa pengekstrakan, isipadu pelarut penyahjerap, masa penyahjerap, pH larutan dan isipadu sampel telah dioptimumkan dan dianalisa menggunakan HPLC-UV-Vis. Di bawah keadaan optimum, kelinearan yang baik telah dicapai dalam julat 1 – 1500 µg L⁻¹ dengan nilai pekali penentuan, R² adalah 0.9921-0.9956. Nilai LOD dan LOQ telah direkodkan dalam julat masing-masing adalah 0.100 - 0.063 dan 0.190 - 0.303 µg L⁻¹. Kaedah GO@Fe₃O₄-DES FF-LPME yang dibangunkan telah digunakan untuk penentuan florokuinolon dalam sampel air dari Lembangan Sungai Langat, Selangor dan pengembalian sebanyak 70.3 – 120.3% diperolehi. Secara kesimpulannya, kaedah penyediaan sampel yang dibangunkan untuk penentuan farmaseutikal terpilih telah menunjukkan sensitiviti dan ketepatan yang baik dan mampu menjadi kaedah alternatif untuk pengekstrakan di dalam sampel air.

**REMOVAL, PRE-CONCENTRATION AND DETERMINATION OF
SELECTED PHARMACEUTICALS FROM ENVIRONMENTAL WATER
SAMPLES**

ABSTRACT

Pharmaceuticals are emerging contaminants that have been widely used in various applications, including human and veterinary medicine, as well as agricultural activities. The pharmaceutical analysis relies on accurate quantification of target pharmaceuticals from a complex matrix, yet this remains a difficult task due to their low concentrations. Therefore, this research demonstrated the use of different sample preparation methods for the determination of selected pharmaceuticals in water samples. A microextraction technique based on vortex-assisted liquid-liquid microextraction with back extraction (VALLME-BE) was developed for the determination of nonsteroidal anti-inflammatory drugs (NSAIDs) namely, ketoprofen, naproxen, diclofenac, and ibuprofen. The procedure was carried out by adding 225 μL of butyl acetate into 10 mL spiked working standard for VALLME procedure, followed by the back-extraction into sodium hydroxide prior to high performance liquid chromatography-UV-Vis (HPLC-UV-Vis) analysis. Under optimum conditions, the proposed technique provided good linearity ($R^2 \geq 0.9809$), repeatability (%RSD; 3.4 – 16.1), and excellent the limits of detection (LOD) and limit of quantification (LOQ) values (ketoprofen (0.134 and 0.407 $\mu\text{g L}^{-1}$), naproxen (0.015 and 0.047 $\mu\text{g L}^{-1}$), diclofenac (0.03 and 0.091 $\mu\text{g L}^{-1}$) and ibuprofen (0.05 and 0.152 $\mu\text{g L}^{-1}$) were obtained. On the other hand, graphene oxide (GO), graphene oxide magnetite (GO@Fe₃O₄), and graphene oxide magnetite-deep eutectic solvent ferrofluid (GO@Fe₃O₄-DES FF) adsorbents were successfully synthesized and characterized.

The removal percentage of fluoroquinolones (ofloxacin, naproxen, gemifloxacin, and sparfloxacin) were optimized based on the batch adsorption method using the synthesized adsorbents. Under the optimum conditions, the adsorption performances of GO@Fe₃O₄ and GO@Fe₃O₄-DES FF were investigated. The experimental data for all the analytes were fitted well with pseudo second-order kinetic model and Freundlich model. The thermodynamic studies showed that the adsorption process was thermodynamically feasible, spontaneous, and exothermic. Finally, as the adsorption performances of GO@Fe₃O₄-DES FF were better than GO@Fe₃O₄, it was further developed for the application of GO@Fe₃O₄-DES FF-liquid phase microextraction (LPME). Several parameters such as type of desorption solvent, ferrofluid volume, extraction time, desorption solvent volume, desorption time, solution pH, and sample volume were optimised and analysed using HPLC-UV-Vis. Under the optimized conditions, good linearity was achieved in the range of 1 – 1500 µg L⁻¹ with a coefficient of determination, R² value of 0.9921-0.9956. The LOD and LOQ value recorded in the range of 0.100 - 0.063 and 0.190 - 0.303 µg L⁻¹, respectively. The developed GO@Fe₃O₄-DES FF LPME method was applied for the determination of fluoroquinolones in water samples from Langat River Basin, Selangor, and the recovery of 70.3 – 120.3% was obtained. In conclusion, the developed sample preparation techniques for the determination of selected pharmaceuticals showed excellent sensitivity and precision and may be an excellent candidate for the extraction of water samples.

CHAPTER 1

INTRODUCTION

1.1 Background of the study

Water is the most abundant and necessary source of life on the planet and it has been declared to be one of the human rights by the United Nations (UN), General Assembly, in 2010 (Onda et al., 2012; Unuabonah et al., 2019). For both personal and household use, everybody has the right to sufficient, constant, safe, appropriate, physically available, and affordable water. Likewise, the 6th Sustainable Development Goal (SDG 6) mandates the access to clean water and sanitation, as well as sound freshwater management. If this aim is not achieved, it will cause serious implications for the survival of life on earth (Unuabonah et al., 2019).

Pharmaceuticals are considered as emerging contaminants and they have been widely employed for a variety of uses, including human and veterinary medicine, and agricultural activities. Pharmaceutically active compounds (PhACs) such as anti-inflammatory drugs, antibiotics, analgesics, X-ray contrast media lipid regulators, estrogens, and beta-blockers have been used worldwide to enhance human and animal health and enhance life expectancy. The consumption of PhACs increased as a result of the world population's increment from 7.6 billion in 2017 to 10 billion in 2050 as expected (Gehrke et al., 2015). Direct discharge of untreated and treated wastewater is the principal source of these pollutants in aquatic environments (Krogh et al., 2017). While livestock farms runoff, agricultural regions, and aquaculture facilities provide a secondary source (Olasupo et al., 2021). In 1970, the first report on the presence of medicines in river water was released (Daughton, 2016). Since then, extensive study has been conducted on the monitoring of pharmaceuticals in aquatic environments.

Pharmaceutical analysis relies on accurate quantification of target pharmaceuticals from a complex matrix, yet this remains a difficult task. Furthermore, analytes are frequently present in the sample matrix at extremely low concentrations, ranging from mg L^{-1} to ng L^{-1} . As the result, increased attention has been placed on establishing sample preparation processes such as preconcentration and pre-treatment over the last few decades. Since it is one of the essential steps that consumes around 80% of the overall quantitative analysis time, using appropriate sample preparation techniques can help tremendously in the development of pharmaceutical analysis. (Daniel et al., 2017; Li et al., 2021).

Many researchers are intrigued by the miniaturization of analytical approaches. By reducing the dimension of conventional analytical methods and the solvents used and the quantity of reagents per analysis, the amount of waste generated is reduced. Therefore, innovative methods to simplify the extraction techniques have been introduced. Microextraction techniques either with solid or liquid extractants have been proposed. Some examples of liquid phase techniques are vortex assisted liquid-liquid microextraction (VALLME), dispersive liquid-liquid microextraction (DLLME) and vortex assist liquid-liquid extraction with back extraction (VALLME-BE) (Shalash et al., 2017). It is clear that the alternative sample pre-treatment that is simple and rapid but sensitive enough to detect low concentration of pharmaceuticals in water samples are required. Towards this end, the plethora of microextraction techniques, VALLME-BE seemed to be the best candidate for sample preparation for pharmaceutical as the extracts were in aqueous phase which able to be analysed using reversed phase HPLC directly without reconstitution step. In addition, the low volume of back extraction provided a high pre-concentration factor which enhanced the response in HPLC analysis.

As an alternative to extracting solvents (in the form of molecular liquids), deep eutectic solvent (DES), ionic liquids (IL), surfactant-based solvents, supercritical fluids, supramolecular solvents, and ferrofluid (FF) are now being considered in microextraction methods. FF or magnetic fluids (MF) are smart colloidal suspensions of single domain magnetic nanoparticles, such as iron oxide (Fe_3O_4), in a polar or non-polar liquid carrier, such as DES, IL, ester, or hydrocarbons (Farahani & Shemirani, 2013). The application of FF is widely seen in bioengineering, microelectronics, and material sciences (Mishra et al., 2014). Different modes of liquid phase microextraction based on FF have recently been discovered and are becoming increasingly popular due to advantages such as ease of use, rapid extraction, and reduced organic solvent use (Safari et al., 2016; Yang et al., 2018; Zohrabi et al., 2016). Furthermore, FF not only eliminates the need for centrifugation to retrieve organic solvents, but it also improves phase separation yield. This results in good extraction efficiency and reproducibility at pre-concentration factors that are acceptable. In general, the magnetic nanoparticles in FF are coated with a shell made of an appropriate material to prevent agglomeration. In this study, choline-chloride based DES was chosen as the carrier liquid. DESs have various advantages over ionic liquids since they are easier and less expensive to produce, as well as being more biodegradable and less hazardous to the environment. DESs are formed when hydrogen bond donors (HBD) and hydrogen bond acceptors (HBA) self-associate to produce eutectic mixtures having lower melting temperatures than the starting compounds (El-Deen & Shimizu, 2019; Sadeghi & Davami, 2019). The magnetic nanomaterial in DES aids in the accumulation of the target analytes due to its van der Waals forces, dipolar attractive interactions, and magnetostatic interactions (Zohrabi et al., 2016).

To form a stable FF, the MNPs must be coated to avoid agglomerations and leaching before being immersed in a carrier liquid. Graphene oxide (GO) has been widely used in sorbent based microextraction techniques. (GO)-based adsorbents have shown great promise to be used as candidates for adsorbents because of their distinct characteristics such as large surface area and small size (Amin et al., 2014; Daniel et al., 2017). However, due to the hydrophilic property of GO, it is difficult to be removed from the sample using traditional separation methods. Hence, it becomes a secondary pollutant and may increase the cost to retreat it. This problem can be solved by anchoring the magnetic properties (Hu et al., 2013). Graphene oxide magnetite (GO@Fe₃O₄) may increase the feasibility of GO with the help of external magnetic fields. This development implies the combination of benefits of adsorption and makes it easy to separate since it involves the use of external magnetic species.

The existing methods for the removal of pharmaceuticals are membrane separation, photochemical degradation, advanced oxidation processes, and adsorption treatments. Adsorption is well regarded as an efficient, effective, and cost-effective approach for removing various contaminants from aqueous solutions in water treatment applications (Dutta & Mala, 2020). Until now, a variety of adsorbents have been developed to reach high adsorption efficiency to remove pharmaceuticals from water and wastewater (Duan et al., 2020; Liu et al., 2018; Okaikue-Woodi et al., 2018; Wang et al., 2020; Yang et al., 2020).

This research demonstrated the development of liquid phase microextraction (LPME) techniques for the determination of pharmaceuticals in water samples, based on the above-mentioned considerations. The VALLME-BE method was developed and applied for the determination of nonsteroidal anti-inflammatory drugs (NSAIDs) as test

compounds. Several optimization parameters such as solvent type and volume, sample solution pH, and vortexing speed and time were studied. On the other hand, new GO based adsorbents were synthesized and characterized. The adsorption performances of the synthesized graphene-oxide magnetite (GO@Fe₃O₄) and graphene-oxide magnetite- deep eutectic solvent ferrofluid (GO@Fe₃O₄-DES FF) were evaluated to explore their potential in batch adsorption of fluoroquinolones (FQs). Finally, GO@Fe₃O₄-DES FF-liquid phase microextraction (GO@Fe₃O₄-DES FF-LPME) method was developed and validated prior to the application for the determination of FQs in environmental water samples collected along Langat River Basin, Selangor, Malaysia.

1.2 Problem statement

NSAIDs have made up more than 15% of all medications found in the environment and they were the most often reported of all classes. On the other hand, FQs are widely utilized not only by people but also in veterinary treatment, particularly in large-scale animal farming. About 50–90% of medicines that are frequently detected in wastewater and receiving surface water bodies were discharged in a mixture of parent and metabolite forms in faecal matter due to inadequate metabolism in people and animals. Owing to their high polarity and solubility in water, the extraction of pharmaceuticals from complex matrices faces significant challenges. Therefore, sample pre-treatment and preconcentration measures play a major role in enhancing the sensitivity and selectivity of the analytical procedure to reach the low limit of detections required for complex matrix analysis, such as aquatic environmental samples.

Thus, the removal of those pollutants and detection of their presence at low concentrations have attracted the attention of many researchers. Several methods such

as photocatalytic degradation, membrane separation, and adsorption have been established to eliminate them. However, these methods are expensive, non-selective, and require pre-treatment. Therefore, to overcome the constraints of conventional methods, numerous miniaturized sample preparation methodologies are widely explored including microextraction techniques. Many other benefits can be highlighted as possible advantages of miniaturization such as improved extraction performance and a widely reduced consumption of samples and chemicals per analysis (with the subsequent reduction in waste generation) is far from being the only driving force behind miniaturization. Instead, several desirable features can be identified for miniaturized methodologies, including Shrinking conventional analytical systems, integration of steps, simplification, enhanced portability, reduced human manipulation, and adequate performance (Pena-Pereira et al., 2021).

More innovative methods can be developed, to accelerate the removal, and extraction processes and to improve the separation of analytes. Nevertheless, a lot of progress is expected to be made with the use of new adsorbents which would make the whole sample preparation process simpler, faster, more economical, more efficient, and more environmental friendly. Hence, the adsorbent provides the surface area necessary to ensure a high extraction recovery and clean up.

In this study, the development of simple microextraction techniques named VALLME-BE for the determination of NSAIDs in environmental water samples was developed. Recent advances in the fabrication of new FF materials, on the other hand, have contributed significantly to the development of miniaturized methods. Given the advantages of GO@Fe₃O₄ adsorbent and DES, a new class of GO@Fe₃O₄-DES FF was

developed for GO@Fe₃O₄-DES FF-LPME of FQs in Langat River Basin, Selangor, Malaysia.

1.3 Objectives

This thesis was dedicated to the development of sample preparation techniques for the determination of selected pharmaceuticals in the environmental water samples.

The specific objectives of this study were:

1. To develop, validate and apply VALLME-BE method for the determination of NSAIDs from environmental water samples.
2. To synthesize, characterize and study the adsorption performances of GO@Fe₃O₄ and GO@Fe₃O₄-DES FF for the removal of FQs using UV-Vis spectrophotometer.
3. To develop, validate and apply GO@Fe₃O₄-DES FF-LPME for the determination of FQs in water samples prior to HPLC-UV-Vis analysis.

1.4 Outline of the thesis

This thesis was divided into five chapters. **Chapter 1** is an introduction that explains the general context of the problem statements and research objectives. In **Chapter 2**, related literature was thoroughly reviewed. In **Chapter 3**, the methodology chapter highlights the chemicals and reagents, and procedures used in these studies. This chapter contains three main parts namely **Part I**, **Part II**, and **Part III**. **Part I** investigated the extraction of ibuprofen (IBU), diclofenac (DIC), ketoprofen (KET), and naproxen (NAP) using VALLME-BE. **Part II** illustrates the synthesis, characterization, and adsorption performances of GO@Fe₃O₄ and GO@Fe₃O₄-DES FF

adsorbents for the removal of FQs. Lastly, **Part III** encompasses the determination of ofloxacin (OFL), enrofloxacin (ENR), sparfloxacin (SPR), and gemifloxacin (GEM) using GO@Fe₃O₄-DES FF based liquid phase microextraction. In the following chapter, **Chapter 4** presents in detail the overall outcomes for results and discussions of the conducted project. Like Chapter Three, this chapter was also divided into three major parts, **Part I, Part II, and Part III**. Characterisation, optimisation, adsorption study, extraction study, method validation, real sample analysis, and reusability studies are all included in these sections, along with their relevant discussions. Finally, **Chapter 5** concludes the overall results as well as future research work recommendations.

CHAPTER 2 LITERATURE REVIEW

2.1 Pharmaceuticals

The advancement production of pharmaceuticals over the last century has resulted in greater disease prevention, increased life expectancy, mortality reduction, and health quality (Ebele et al., 2017). Pharmaceuticals have been identified as emerging contaminants (ECs), due to continuous discharge and prevalence of the trace quantities of the pharmaceutical components in the environment (Yu et al., 2011). Pharmaceuticals penetrate water bodies through multiple pathways, including human excretion, medications disposal, livestock husbandry, agricultural and pharmaceutical industries. In addition, inefficient elimination of pharmaceuticals during the treatment process in waste-water treatment plants (WWTPs) and water treatment plants (WTPs) also contributed to this issue (Boxall et al., 2012; Morales et al., 2016; Petrie et al., 2014).

The occurrence of certain pharmaceutical compounds in surface water bodies, even at low concentrations, can constitute a significant environmental risk. The removal of these compounds is a primary consideration in a variety of fields of research. Furthermore, as a result of population growth and high pharmaceutical usage, the concentration of pharmaceuticals in the aquatic environment is gradually growing. Several investigations have discovered several pharmaceuticals in surface water, wastewater treatment plant effluents, and groundwater (Chen et al., 2015; Golet et al., 2002; Sturini et al., 2012; Vázquez et al., 2012).

Unfortunately, even though pharmaceuticals are considered as ECs, no legislative maximum residue limits (MRLs) for aquatic ecosystems have been

established especially in Malaysia. Despite the fact that pharmaceutical-related industries must adhere to stringent legislation in the healthcare sector, with continuous monitoring from agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), environmental concerns have lagged behind. Only recently some global actions have reflected the increased concern of both the scientific community and legislative authorities about environmental pharmaceuticals. Agencies such as the US Food and Drugs Administration (US FDA) and legislature such as the European Union Water Framework Directive have established guidelines for the evaluation and use of certain pharmaceuticals. Furthermore, in 2009, the US Environmental Protection Agency (US EPA) classified several unregulated ECs comprising potential health hazards in the contaminant candidate List 3 for drinking water. Under the EU Water Framework Directive (WFD-2000/60/EC), pharmaceuticals such as diclofenac have been identified as a priority contaminant in surface water bodies (2013/39/EU, 2013; Stewart et al., 2014).

Pharmaceuticals are a large group of substances that are categorized into several categories. such as analgesics and antibiotics, anti-inflammatory drugs, anti-epileptics, beta-blockers, hormones, cytostatics, disinfectants, antidepressants, and antiseptics. Studies revealed that antibiotics and nonsteroid anti-inflammatories (NSAIDs) are the most typically found in water since these groups possessed the highest risk and are widely used pharmaceuticals to alleviate infections and inflammation (Taoufik et al., 2020).

2.1.1 Nonsteroidal anti-inflammatory drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to alleviate inflammatory, chronic, and acute pain conditions. NSAIDs have antipyretic and analgesic properties as well. This includes diclofenac, ibuprofen, ketoprofen, and

naproxen which are in the top ten persistent pollutants found in wastewater properties (Abd Wahib et al., 2018; Wong, 2019). The consumption of NSAIDs increasing rapidly since the first developed and marketing in 1899. This is parallel with the subsequent release of these pharmaceuticals in the water bodies (Thalla & Vannarath, 2020). NSAIDs have been identified as hazardous residues among pharmaceuticals, according to the International Council Directive 96/23/EC study (Tanwar et al., 2015). In particular, diclofenac was added to the list of priority substances of the European Commission. Prolonged use of these drugs, however, may result in substantial water contamination due to human excretion or inadequate disposal due to low degradation factors and polarity.

As a result of their well-known toxicity and negative effects, there is a lot of interest in monitoring and determining NSAIDs in environmental samples using sensitive, selective and repeatable analytical techniques. Several methods for determining NSAIDs have been reported such as solid-phase microextraction (SPME) (Sulej-Suchomska et al., 2016), single-drop microextraction (SDME) (Azzouz et al., 2010), dispersive liquid-liquid microextraction (DLLME) (Zgoła-Grześkowiak, 2010), and hollow fiber liquid-phase microextraction (LPME) (Es'haghi, 2009) as stated in Table 2.1.

Table 2.1 Sample preparation techniques for NSAIDs analysis.

| Analyte | Matrix | Instrument | Method | Extraction solvent/volume | Extraction time (mins) | LOD ($\mu\text{g L}^{-1}$) | Recovery (%) | EF | Ref |
|---------------------------|------------------------|-------------------|--------------------------|--|------------------------|------------------------------|--------------|---------|--------------------------------------|
| NAP KET IBU DIC | Biological fluids | GC-MS HPLC-DAD | DLLME-BE | 200 μL n-dodecane/ TOPO (95:5) | 11 | 0.10-1 0.1- 6.0 | 86.8-1-5.2 | - | (Ghambarian et al., 2020) |
| KET DIC | Urine | HPLC | DLLME-SFO | 20 μL 1-undecanol dispersed in 100 μL ACN | 9 | 5.20 – 4.70 | 95.7-115.6 | – | (Shukri et al., 2015) |
| DIC IBU | Urine | GC-FID | USE-AALLME and LDS-DLLME | 30 μL 1-octanol | 10 | 0.10 - 1.00 | 94-103 | 115-135 | (Barfi et al., 2015) |
| KET DIC IBU | Tap and river water | HPLC-UV/FP | Vortex-IL-DLLME | 90 μL [BMIM] [PF ₆] 210 μL methanol | 6 | 17.00 – 95.00 | 89-103 | 49-57 | (Toledo-neira & Álvarez-lueje, 2015) |
| IBU DIC | Human plasma and urine | HPLC | LDS-AALLME | n-octanol 65 μL | 15 | 1.10 - 1.70 | 94-102 | 50-61 | (Barfi et al., 2015) |
| KET NAP, DIC IBU | Wastewater | HPLC | DLLME-SFO | 30 μL 1-undecanol 150 μL ACN | 10 | 0.04 - 0.13 | < 80 | 283-302 | (Beldean-Galea et al., 2015) |
| NAP DIC IBU | Biological samples | HPLC | AALLME-BE | Chloroform 80 μL | 10 | 0.20– 0.52 | 78-94 | 390-470 | (Farajzadeh et al., 2015b) |

Table 2.1 (continued)

| Analyte | Matrix | Instrument | Method | Extraction solvent/volume | Extraction time (mins) | LOD ($\mu\text{g L}^{-1}$) | Recovery (%) | EF | Ref |
|-------------------|------------------------|------------|-------------|---|------------------------|------------------------------|--------------|---------|--------------------------|
| NAP DIC IBU | Tap and drinking water | UHPSFC-PDA | US-IL-DLLME | 85 mg [C ₈ MIM][PF ₆] 0.5 mL ACN | 11 | 0.62 - 7.37 | 88-111 | 255-340 | (Vázquez et al., 2013) |
| KET NAP | Human urine | HPLC | IL-dLPME | 280 μL [BMIM PF ₆] 720 μL methanol | 5 | 55.00 – 70.00 | 99.6-107 | 42-36 | (Cruz-vera et al., 2009) |

KET; ketoprofen, NAP; naproxen, DIC; diclofenac, IBU; ibuprofen; US-DLLME; ultrasound-assisted dispersive liquid–liquid microextraction, DLL-SDME; dispersive liquid–liquid and single-drop microextraction, USE-AALLME; ultrasound-enhanced air-assisted liquid–liquid microextraction, LDS-DLLME; low-density solvent-based dispersive liquid–liquid microextraction, Vortex–IL–DLLME; ionic liquids dispersive liquid–liquid microextraction, LDS–AALLME; low density solvent-based air-assisted liquid–liquid microextraction, DLLME-SFO; dispersive liquid–liquid microextraction and solidification of floating organic droplets, AALLME–BE; air-assisted liquid–liquid microextraction - back extraction, US–IL–DLLME; ultrasound-assisted ionic liquid dispersive liquid–liquid, IL–dLPME; ionic liquid-based dispersive liquid–liquid microextraction, VALLME-BE; vortex assist liquid liquid microextraction-back extraction, ([BMIM][PF₆]); 1-butyl-3-methylimidazolium hexafluorophosphate, [C₈MIM][PF₆]; 1-octyl-3-methylimidazolium hexafluorophosphate, TOPO; potassium hydroxide, trioctylphosphine oxide, EF; enrichment factor

2.1.2 Antibiotics

Antibiotics are now produced by chemical synthesis or chemical modification of natural substances (Kovalakova et al., 2020; Wang et al., 2019). They are biologically active compounds with antibacterial, antiparasitic, and antifungal properties that have been created as medications for human and animal illnesses, as well as food supplements for preventing disease in animal husbandry (Hu et al., 2018). The global consumption of antibiotics is rising in tandem with the world's growing human population. Furthermore, the rising demand for animal protein is intensifying food production, forcing the use of more growth promoters and antibiotics to keep the supply stable (Kovalakova et al., 2020; Wang et al., 2016)

The occurrence of antibiotics in environmental water may cause the occurrence of antibiotic resistance genes (ARGs) and antibiotic-resistant bacteria (ARB). ARB can release or transmit ARG in aquatic environments, which are rather persistent and can be acquired by other bacteria, resulting in an increase in ARB. Antibiotics also encouraged the proliferation of ARG in aquatic environments (Shao et al., 2018; Xu et al., 2019). ARGs can be transmitted to non-bacterial creatures, such as humans, to reduce their susceptibility to antibiotics. The proliferation and pollution of antibiotics and ARGs in environmental water systems have garnered widespread and growing attention as a serious hazard to human health. ARGs have been identified as emergent environmental pollutants because of their antibiotic resistance and threat to environmental safety and human health (Zhang et al., 2021). Besides, antibiotics also have toxic effects on aquatic species due to bioaccumulation and biomagnification (Wu et al., 2015).

Antibiotics including tetracycline, fluoroquinolone, sulfonamides, chloramphenicol, and macrolide are complex compounds that are difficult to analyse in environmental samples due to co-extracted components that are dependent on the analyte-sample combination and thus obstruct quantification, which is known as ion suppression effects. Fluoroquinolones (FQs) are a class of relatively new synthetic antibiotics. FQs are registered under the National Pharmaceutical Regulatory Agency (NPRA) of the Ministry of Health Malaysia and identified by WHO as critically important medicines for the human health and veterinary sector (WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), 2011). FQs are among the most widely found antibiotics in the environment. Despite their inherent risks, FQs have garnered less attention than other pollutants, thus the risk they pose in effluents is uncertain (Ding et al., 2020). FQs are generally partially immobilized within the human and animal body, with 20 to 80 % being released into the environment in pharmacologic active forms (Dutta and Mala, 2020). FQs were found in wastewater effluents and sewage sludge (Golet et al., 2002), soils (Salvia et al., 2015), surface waters (Sturini et al., 2012), and groundwater (Vázquez et al., 2012).

Researchers are increasingly concerned about these harmful antibiotics from the aquatic environment. Membrane separation, ozonation, advanced oxidation processes (AOPs), photochemical degradation, and adsorption treatments are some of the methods used to remove antibiotics. Adsorption is becoming increasingly vital for the removal of FQs due to its ease of operation, lack of by-products high efficiency, low cost, and availability of many adsorbents. Adsorption techniques have been used in numerous studies to remove FQs from environmental water using a plethora of adsorbent materials, including clay minerals (Peng et al., 2018; Speltini et al., 2017; Xiang et al., 2020). Table 2.2 describes different adsorbents used for the adsorption of FQs.

Table 2.2 Removal of FQs using different adsorbents.

| Adsorbent | Analytes | $Q_{e,exp}$ ($mg\ g^{-1}$) | Ref |
|---|------------|---------------------------------|-------------------------|
| Nanoscale zero-valent iron (NZVI) | OFL | 48.9 | (Zhao et al., 2020) |
| Chitosan- polyacrylic acid | ENR | 387.7 | (Wang et al., 2019) |
| Humic acid coated magnetic biochar | ENR | 1.7 | (Zhao et al., 2019) |
| Fe ₃ O ₄ /GO/citrus peel-derived magnetic bio-char nano- composite (mGOCP) | SPR | 502.4 | (Zhou et al., 2019) |
| Polypyrrole modified <i>Calotropis gigantea</i> fiber (PPy-O-CGF) | ENR | 78.3 | (Duan et al., 2019) |
| Metal-organic framework with polar – SO ₃ H (MIL-101(Cr)–SO ₃ H) | ENR | 408.2 | (Guo et al., 2019) |
| Lignocellulosic substrate | ENR | 91.5 | (Sayen et al., 2018) |
| Bamboo biochar | ENR OFL | 45.9 | (Wang et al., 2015) |
| TiO ₂ -modified zeolites | ENR | 3.0 | (Maraschi et al., 2014) |
| Polydopamine-coated graphene oxide/Fe ₃ O ₄ (PDA@ GO/Fe ₃ O ₄) imprinted nanoparticles | SPR | 70.9 | (Tan et al., 2017) |
| Graphene oxide (GO) | OFL | 0.048 mmol/g | (Yadav et al., 2018) |
| Magnetic carboxylated cellulose nanocrystals with molecularly imprinted polymer (M-CCNs@MIP) | OFL | 45.6 | (Hu et al., 2018) |
| Layered double hydroxides (LDHs) onto cotton fiber | ENR | 20.5 | (Wang et al., 2018) |
| Magnetic biochar-based manganese oxide composite (MMB) | ENR | 7.2 | (Li et al., 2018) |

OFL; ofloxacin, ENR; enrofloxacin, GEM; gemifloxacin, SPR; sparfloxacin.

Despite the benefits of nanoadsorbents for FQs adsorption, manipulating them from solution takes time since they have a high back-pressure in dynamic mode and require centrifugation and filtering in static batch mode. Hence, the analysis of FQs using liquid phase microextraction (LPME) was explored for different samples including food samples, biological samples (Moema et al., 2012), and water samples. Table 2.3 summarizes the FQs sample preparation based on LPME.

2.2 Sample preparation

The importance of sample preparation in the chemical analysis workflow has been recognized. As a result, substantial efforts have been undertaken in recent years to improve the overall sample preparation method. Without a doubt, sample preparation is among the most critical steps in the analytical process. Overall, it is the most time-consuming aspect of developing an analytical process and is regarded as a significant source of errors in analysis (Owczarek & Guardia, 2017). Sample preparation is expected to account for about 80% of the workload, time, and expense. The primary goals of sample preparation are to remove possible interferences, preconcentrate the analyte and transform the analyte (if necessary) into a more suitable form for detection or separation (Płotka-wasyłka & Szczepan, 2015). The choice of a preparation method is determined by: (1) the analyte(s) concentration level(s), (2) the instrumental measurement technique, (3) the sample matrix, and (4) the appropriate sample size. Furthermore, sample preparation allows for the preconcentration and/or isolation of analytes, enhancing the selectivity and sensitivity of determination procedures (Tartaglia et al., 2019).

Table 2.3 FQs sample preparation based on LPME.

| Analyte | Method | Sample preparation | Matrix | Extraction solvent | LOD | Recovery (%) | Ref |
|---------------------------------|---------|----------------------|----------------------|--|---------------------------------|--------------|-------------------------|
| FLE, OFL, NOR, CIP and ENR | HPLC | ILSDME | Swin feed | [C ₈ MIM][PF ₆] | 0.07–0.61 $\mu\text{g kg}^{-1}$ | 90.6–103.2 | (Wang et al., 2016) |
| NOR, CIP, DAN, ENR, SAR and DIF | HPLC | DLLME | Chicken liver | MeCN | 5 - 19 $\mu\text{g kg}^{-1}$ | 62–106 | (Moema et al., 2012) |
| OFL, NOR, CIP and ENR | HPLC | in situ hDES-SA-LLME | Surface water | hydrophobic deep eutectic solvents | 3.0 ng mL^{-1} | - | (Li et al., 2020) |
| OFL, CIP and ENR | HPLC | HF-LPME | Milk | [OMim][BF ₄] | 0.05 - 0.01 mg mL^{-1} | 58-78 | (Han et al., 2012) |
| OFL and CIP | HPLC | HF-LPME | Plasma and tap water | 1-octanol | 0.5 $\mu\text{g L}^{-1}$ | 88 – 108 | (Esrafilı et al., 2012) |
| DAN, NOR, ENR and CIP | HPLC-UV | MIP-HFM | Water and urine | Toluene | 0.1–10 $\mu\text{g L}^{-1}$ | - | (Barahona et al., 2019) |

Fleroxacin (FLE), ofloxacin (OFL), norfloxacin (NOR), ciprofloxacin (CIP), enrofloxacin (ENR), norfloxacin (NOR), sarafloxacin hydrochloride (SAR), danofloxacin (DAN), difloxacin hydrochloride (DIF). ionic-liquid-based, salt-induced, dual microextraction (ILSDME), 1-butyl-3-methylimidazolium tetrafluoroborate [OMim][BF₄], Molecularly imprinted polymer- hollow fiber microextraction (MIP-HFM), in situ formation of hDES coupled with shaker-assisted LLME (in situ hDES-SA-LLME), liquid phase microextraction using a hollow fibre (HF-LPME), 1-octyl-3-methylimidazolium hexafluorophosphate ([C₈mim]PF₆)

The appropriate sample preparation procedure should meet the following criteria: (i) fast and simple implantation in any laboratory, (ii) eliminating or minimizing matrix interferences to minimize their impact on the instrument and create a clean extract, (iii) enhancing analyte sensitivity or selectivity (iv) low-cost materials and reagents, (v) environmentally friendly solvents and reagents, (vi) giving optimistic forms for analytes' instrumental analysis and ensuring a repeatable analysis procedure, (vii) sufficient to several analytes in fewer steps, and (ix) low energy consumption (Smith, 2003).

For the extraction of pharmaceuticals, liquid-liquid extraction (LLE) and solid-phase extraction (SPE) are two widely utilized and well-established sample preparation techniques. Traditional techniques, on the other hand, have a number of fundamental limitations, including costly and time-consuming procedures, the need for a considerable volume of organic solvents, and material and automation challenges. (Manousi et al., 2017; Samanidou, 2018). Recent sample preparation developments have concentrated on the replacement of procedures with nanosorbents, miniaturized, and environmentally friendly techniques.

As a result, new sorts of microextraction procedures, such as liquid liquid microextraction (LLME), have been developed, dispersive liquid liquid microextraction (DLLME) and vortex assisted liquid liquid microextraction (VALLME) as replacements for the classical LLE (Burato et al., 2020). Microextraction methods based on eliminating or reducing organic solvents and reagents for sorbent conditioning and elution, on the other hand, can be used to miniaturize SPE methods. Various miniaturized SPE methodologies have been developed in this regard, including solid-phase microextraction (SPME), micro-solid phase extraction (μ -SPE), stir-bar sorptive

extraction (SBSE), microextraction in a packed syringe (MEPS) and dispersive-micro solid phase extraction (D- μ -SPE) (Ali et al., 2020; Płotka-wasyłka et al., 2015). Depending on the extraction phase used, a sample preparation process can be characterized as solvent-based or solid-based extraction. Figure 2.1 illustrates major extraction techniques that are commonly used by researchers.




Figure 2.1 Major microextraction techniques

2.2.1 Solvent-based microextraction

Due to their high toxicity, costly disposal necessitates, and impact on future pollution problems, liquid-liquid extraction, and its various approaches have been under intense scrutiny for the past decade, enabling the development of liquid phase microextraction (LPME) (Burato et al., 2020; An et al., 2020). A number of approaches evolved in a short period of time, all with the objective of decreasing the quantity of solvent needed in the sample preparation procedure. In solvent microextraction, the analyte was extracted into a small volume of immiscible solvent (acceptor phase) from the sample solution (donor phase) (Soares da Silva Burato et al., 2020) (Burato et al., 2020). In 1995, the use of solvent-based microextraction was first documented. The first droplet-based analytic approach was developed by Liu and Dasgupta (1995). Since then, a number of approaches have been developed, all of which have a high sample-to-acceptor phase ratio as a common feature (Ma et al., 2011).

Table 2.4 summarizes major modifications of solvent-based microextraction techniques. Solvent base extraction has several benefits, including the need for a low volume of organic solvent, rapid, simple, low cost, and the ability to combine extraction, clean up, and preconcentration in one step. Numerous investigations on enhancing solvent microextractions have shown that the bulk of the suggested methods are insufficient and have yet to be regarded as a viable alternative to LLE.

To preserve the suspended drop, the SDME method was replaced by the HF-LPME (acceptor phase, AP). The two-phase and three-phase HF-LPME have been developed, with the latter being particularly important due to its direct application for HPLC and capillary electrophoresis (CE) studies. Although the electromembrane method (Bello-López et al., 2012) has decreased the lengthy extraction time (30–40

min), the limited repeatability has prompted scientists to look for other non-fiber microextraction strategies (Ojeda & Rojas, 2018). The DLLME, which was initially released in 2006, has attracted a lot of attention (Rezaee et al., 2006).

The DLLME method uses a dispersive solvent to enhance dispersion and thus increase the contact area between the organic phase (AP) and the aqueous material (donor phase, DP), which is important for rapid extraction (Rezaee et al., 2010). The use of dispersive solvents, on the other hand, may reduce the analytes' mass transfer and fractionation into the extraction solvent, lowering the extraction efficiency (Yiantzi et al., 2010). Another drawback of this approach is the use of high volume and hazardous organic solvents (Leng et al., 2012; Rezaee et al., 2006). An alternative dispersive technique known as VALLME has been designed to tackle the shortcomings of the DLLME technique (Yiantzi et al., 2010).

Significant progress has been made in the production of liquid magnetic materials in recent years, with ferrofluids (FFs) being a prominent example. (Clark et al., 2016; Sajid, 2019). Magnetic nanoparticles (MNPs) are dispersed in a carrier liquid to form FFs. A FF can be composed of three parts: magnetic particles, a coating, and a carrier liquid. To form a stable ferrofluid, the carrier liquid should have adequate interactions with the MNPs. To improve the distribution performance of the extractant, it must be insoluble in the aqueous medium and have a low vapour pressure to avoid any degradation during the microextraction method (Kokosa, 2019). As a result, researchers have experimented with various solvents for ferrofluid synthesis the most common carrier such as, organic solvents, ionic liquid, DES, and supramolecular solvents.

Table 2.4 Major modification on solvent microextraction techniques

| Technique | Modification | Brief description and remarks | Ref |
|-----------|---|--|--------------------------|
| | Continue flow microextraction (CFME) | Continuous flow of sample solution through extracting drop that trapped in a glass chamber. <u>Remarks:</u> high EF, limit to non-polar analytes, and need additional equipment. | (Werner et al., 2018) |
| | Solidified floating organic drop microextraction (SFODME) | Freely rotating organic solvent drop that separated from sample upon solidification by cooling an ice bath. <u>Remarks:</u> smaller drop led to higher EF, and limited choices of solvent according to melting point and solubility | (Thongsaw et al., 2017) |
| 23 | SDME | Three phase mode An aqueous drop immersed in the organic drop. The analytes extracted from sample to the organic drop then back extracted to the aqueous drop. <u>Remarks:</u> Ideal for both acidic and basic analytes. | (Garc, 2016) |
| | Drop to drop SDME (DD-SDME) | The sample is a drop (in microliters) <u>Remarks:</u> shorter extraction time, and suitable for low sample volume | (Shrivasa & Kumar, 2011) |
| | Dynamic mode SDME | Repeated cycle (30-90) of the drop in and out the sample solution <u>Remarks:</u> efficiency improved | (Wang et al., 2014) |
| | Solid matrix support microextraction (SSME) | The suspended drop supported by the solid matrix <u>Remarks:</u> Improve drop stability | (Gao et al., 2012) |

Table 2.4 (continued)

| Technique | Modification | Brief description and remarks | Ref |
|-----------|---|---|-------------------------|
| HF-LPME | Electro membrane extraction (EME) | Electrokinetic migration of the analyte caused by electric field across the hollow fiber membrane. <u>Remarks:</u> less than 5 mins extraction time. | (Han & Row, 2012) |
| | Hollow fiber solid-liquid phase microextraction (HF-SLPME) | A solid phase sorbent immobilized in the pores of the hollow fiber and used after impregnating in an organic solvent. <u>Remarks:</u> Faster extraction since it takes place in the pores | (Hamedi, 2017) |
| DLLE | Solvent bar microextraction (SBME) | HF piece is freely rotated in the sample. The two ends of the hollow fiber are sealed after filling with the extraction solvent. <u>Remarks:</u> Higher extraction efficiency due to more exposure | (Herce-Sesa, 2018) |
| | Ultrasound-assisted emulsification-microextraction (USAEME) | Use of ultrasound irradiation instead of dispersing solvent. <u>Remarks:</u> Less solvent used | (Sereshti et al., 2019) |
| | Vortex assisted liquid liquid microextraction (VALLME) | Use of vortexing instead of dispersing solvent to increase contact surface. <u>Remarks:</u> Less solvent used | (Makahleh et al., 2015) |
| | Air-assisted liquid-liquid microextraction (AALLME) | Fine droplets of the microextraction solvent formed due to pumping of a mixture of DP/AP in and out of a syringe. Disperse solvent free technique. <u>Remarks:</u> Less solvent used | (Barfi, et al., 2015) |